Efficacy and safety of switching from adalimumab to baricitinib: phase 3 data in patients with rheumatoid arthritis
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Conference item |
| Published: |
Journal of Rheumatology
2017
|
| _version_ | 1797053205671051264 |
|---|---|
| author | Taylor, P Keystone, E Ortmann, R Issa, M Xie, L Muram, D Bradley, J De Bono, S Rooney, T Tanaka, Y Faraawi, R |
| author_facet | Taylor, P Keystone, E Ortmann, R Issa, M Xie, L Muram, D Bradley, J De Bono, S Rooney, T Tanaka, Y Faraawi, R |
| author_sort | Taylor, P |
| collection | OXFORD |
| description | |
| first_indexed | 2024-03-06T18:40:41Z |
| format | Conference item |
| id | oxford-uuid:0cc26971-653f-49e2-bddb-b20f03f2d0d5 |
| institution | University of Oxford |
| last_indexed | 2024-03-06T18:40:41Z |
| publishDate | 2017 |
| publisher | Journal of Rheumatology |
| record_format | dspace |
| spelling | oxford-uuid:0cc26971-653f-49e2-bddb-b20f03f2d0d52022-03-26T09:36:44ZEfficacy and safety of switching from adalimumab to baricitinib: phase 3 data in patients with rheumatoid arthritisConference itemhttp://purl.org/coar/resource_type/c_c94fuuid:0cc26971-653f-49e2-bddb-b20f03f2d0d5Symplectic Elements at OxfordJournal of Rheumatology2017Taylor, PKeystone, EOrtmann, RIssa, MXie, LMuram, DBradley, JDe Bono, SRooney, TTanaka, YFaraawi, R |
| spellingShingle | Taylor, P Keystone, E Ortmann, R Issa, M Xie, L Muram, D Bradley, J De Bono, S Rooney, T Tanaka, Y Faraawi, R Efficacy and safety of switching from adalimumab to baricitinib: phase 3 data in patients with rheumatoid arthritis |
| title | Efficacy and safety of switching from adalimumab to baricitinib: phase 3 data in patients with rheumatoid arthritis |
| title_full | Efficacy and safety of switching from adalimumab to baricitinib: phase 3 data in patients with rheumatoid arthritis |
| title_fullStr | Efficacy and safety of switching from adalimumab to baricitinib: phase 3 data in patients with rheumatoid arthritis |
| title_full_unstemmed | Efficacy and safety of switching from adalimumab to baricitinib: phase 3 data in patients with rheumatoid arthritis |
| title_short | Efficacy and safety of switching from adalimumab to baricitinib: phase 3 data in patients with rheumatoid arthritis |
| title_sort | efficacy and safety of switching from adalimumab to baricitinib phase 3 data in patients with rheumatoid arthritis |
| work_keys_str_mv | AT taylorp efficacyandsafetyofswitchingfromadalimumabtobaricitinibphase3datainpatientswithrheumatoidarthritis AT keystonee efficacyandsafetyofswitchingfromadalimumabtobaricitinibphase3datainpatientswithrheumatoidarthritis AT ortmannr efficacyandsafetyofswitchingfromadalimumabtobaricitinibphase3datainpatientswithrheumatoidarthritis AT issam efficacyandsafetyofswitchingfromadalimumabtobaricitinibphase3datainpatientswithrheumatoidarthritis AT xiel efficacyandsafetyofswitchingfromadalimumabtobaricitinibphase3datainpatientswithrheumatoidarthritis AT muramd efficacyandsafetyofswitchingfromadalimumabtobaricitinibphase3datainpatientswithrheumatoidarthritis AT bradleyj efficacyandsafetyofswitchingfromadalimumabtobaricitinibphase3datainpatientswithrheumatoidarthritis AT debonos efficacyandsafetyofswitchingfromadalimumabtobaricitinibphase3datainpatientswithrheumatoidarthritis AT rooneyt efficacyandsafetyofswitchingfromadalimumabtobaricitinibphase3datainpatientswithrheumatoidarthritis AT tanakay efficacyandsafetyofswitchingfromadalimumabtobaricitinibphase3datainpatientswithrheumatoidarthritis AT faraawir efficacyandsafetyofswitchingfromadalimumabtobaricitinibphase3datainpatientswithrheumatoidarthritis |